Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
New Mouse Model Links Mitochondria to Parkinson Disease
18 January 2007. Take a deep breath. Mitochondrial respiration problems could be central to Parkinson disease (PD) pathology. That’s according to Nils-Göran Larsson and colleagues at the Karolinska Institute, Stockholm, Sweden. In this week’s PNAS online, the researchers describe how mitochondrial deficiency in midbrain dopaminergic neurons mimics this devastating disease in mice rather faithfully, with late-onset and slowly progressing neurological symptoms. The results suggest that damage to mitochondria is sufficient to cause Parkinson’s-like neurodegeneration.

Mitochondria are the cell’s generators, pumping out heat and the high-energy compounds that drive power-hungry processes such as muscle contraction, protein synthesis, and neurotransmitter release—neurons are laden with the tiny organelles. This is not the first time mitochondria have been linked to neurodegenerative diseases. Toxic reactive oxygen species generated by the mitochondrial respiratory chain and mutations in mitochondrial DNA (mtDNA) are both suspects in Parkinson disease pathology (see ARF related news story). Yet it has been difficult to determine with certainty if mitochondrial damage is the cause or merely an effect of PD. Even in the case of MPTP, a mitochondrial toxin responsible for some rare cases of Parkinson’s, it is unclear if the disease directly results from damage to mitochondria in midbrain dopaminergic (DA) neurons that are primarily affected by the disease, or whether other MPTP toxicities or damage to other areas of the brain play a role. The strength of this new study is that it specifically probes the role of those DA neurons.

Larsson and colleagues took advantage of the widely used Cre-lox recombination system that selectively removes pieces of DNA from the genome. First author Mats Ekstrand and colleagues trained the system on the gene for mitochondrial transcription factor A (Tfam). Tfam is essential for healthy mitochondria because it not only controls the amount of DNA made in each organelle, but, as a master transcription factor, it also controls expression of mitochondrial genes. The mitochondrial genome encodes 13 key subunits of the respiratory chain (most other mitochondrial genes are actually encoded in the nucleus), and therefore loss of Tfam might be expected to have serious consequences for oxidative respiration. And that’s just what Ekstrand and colleagues found.

The scientists crossed mice expressing Cre recombinase under the control of the dopamine transporter gene with mice expressing Lox-flanked Tfam alleles. The resulting MitoPark mouse strain has a homozygous disruption of Tfam in midbrain DA neurons and an unhealthy loss of cytochrome c oxidase (Cox) to boot. Cox catalyzes the very last of the respiratory chain reactions, and without it the complete pathway slows to a crawl.

What are the physiological consequences of slowing down respiration in these mitochondria? Young mice appeared to cope just fine; however, by 14-15 weeks they began to tremble, twitch, and their limbs became rigid—all tell-tale signs of parkinsonism. After a single dose of L-dopa, the treatment of choice for people with Parkinson’s, the mice improved considerably. However, much like in human cases, the drug proved less and less effective as the animals aged.

The symptoms can be explained by a gradual loss of DA neurons in the dorsolateral striatum beginning around week 12. This was more apparent in the substantia nigra, the area most badly affected in Parkinson’s patients. Even earlier, at about 6 weeks, the researchers detected the accumulation of cytoplasmic aggregates. These did not contain α-synuclein, a major component of the Lewy bodies found in the neurons of people with PD. The exact nature of the aggregates is unclear, but the fact that a double membrane reminiscent of the mitochondrial membrane surrounded some of them suggests that they may represent mitochondrial degradation products. Indeed, the authors speculate that “…reduced mtDNA expression may lead to an aggregation of nucleus-encoded proteins in the mitochondria of DA neurons, and that that event could initiate an aggregation process also involving non-mitochondrial proteins.”

The similarities between this new mouse phenotype and Parkinson’s pathology suggest that the disease may, at least in some cases, start in the mitochondria. Whether this means reactive oxygen species play a role is unclear. The MitoPark mouse may help answer this vexing question about the disease.—Tom Fagan

Reference:
Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, Trifunovic A, Hoffer B, Cullheim S, Mohammed AH, Olson L, Larsson N-G. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. PNAS Early Edition. January 15, 2007. Abstract

 
Comments on News and Primary Papers
  Primary Papers: Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons.

Comment by:  Mark Cookson
Submitted 18 January 2007  |  Permalink Posted 18 January 2007

This paper supports the longstanding hypothesis that mitochondrial derangements are sufficient to cause cell death in nigral neurons, which may be an important clue for Parkinson disease. There is some later cell loss in the ventral tegmental area, which differs from Parkinson disease and from other models, and presumably if Tfam had been knocked out in other neurons, as well, one might see loss in other brain regions. We cannot quite conclude from these experiments alone that mitochondrial damage is sufficient to cause PD. But when added to the emerging evidence from genetic parkinsonism, where mitochondrial function is also implicated, the results suggest that mitochondrial function is important for maintenance of neuronal function and survival.

These mice obviously have great potential utility in testing therapies aimed at preventing the symptoms of PD. Ekstrand et al. show that the mice respond to the major (symptomatic) therapy available for PD, that is, L-dopa. It is very interesting to see that there is an aging component to the responsiveness to L-dopa, which might...  Read more


  Primary Papers: Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons.

Comment by:  M. Flint Beal
Submitted 18 January 2007  |  Permalink Posted 18 January 2007

This is a very interesting paper. It clearly shows that select loss of mitochondrial function in midbrain dopaminergic neurons can lead to a progressive respiratory chain deficiency, which then leads to inclusion formation and loss of dopaminergic neurons. The study is very well done. The authors have characterized the mice behaviorally. They have shown motor deficits, which respond to L-dopa therapy. The progressive development of the loss of midbrain neurons had several of the key features of PD. It showed adult-onset neurodegeneration, slowly progressive clinical course, earlier onset of cell death, and more extensive cell death in the substantia nigra than the ventral tegmental area, as well as the development of inclusions. The inclusions proved not to be α-synuclein-positive. They contained mitochondrial proteins as well as membrane components.

The strength of this is that it is a slowly evolving model of PD. It also ties in to recently observed marked increases in mitochondrial deletions in the substantia nigra, which occur in laser-dissected individual dopaminergic...  Read more


  Comment by:  Mary Reid
Submitted 18 January 2007  |  Permalink Posted 19 January 2007

It's of interest these signs of Tfam deficiency occur with age. SIRT1 is an activator of peroxisome proliferation-activated receptor-γ coactivator-1 α (PGC-1α) which has been shown to increase Tfam (1,2). Perhaps the changes seen in this model may not only occur in Parkinson's but may also reflect the aging process. It would be interesting to see whether resveratrol, an activator of SIRT1 and PGC-1α, may prevent or delay the signs of Parkinson's reported to occur in these mice at 14-15 weeks. The study by Lee and colleagues (3) finding reduced Tfam in the fetus with DS would have me question why more extensive neuronal loss in the substantia nigra is not reported in that condition. Mann et al. (4) report loss of pigmented dopaminergic nerve cells from the ventral tegmental area in patients with Down syndrome at middle age.

References:
1. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006 Dec 15;127(6):1109-22. Epub 2006 Nov 16. Comment in: Cell. 2006 Dec 15;127(6):1091-3. Abstract

2. Choi YS, Hong JM, Lim S, Ko KS, Pak YK. Impaired coactivator activity of the Gly482 variant of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) on mitochondrial transcription factor A (Tfam) promoter. Biochem Biophys Res Commun. 2006 Jun 9;344(3):708-12. Epub 2006 Apr 17. Abstract

3. Lee SH, Lee S, Jun HS, Jeong HJ, Cha WT, Cho YS, Kim JH, Ku SY, Cha KY. Expression of the mitochondrial ATPase6 gene and Tfam in Down syndrome. Mol Cells. 2003 Apr 30;15(2):181-5. Abstract

4. Mann DM, Yates PO, Marcyniuk B. Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle age. J Neurol Neurosurg Psychiatry. 1987 Mar;50(3):341-4. Abstract

View all comments by Mary Reid

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad